Neuren Pharmaceuticals Limited (ASX: NEU)
Sector: Health Care
Market cap: A$2.6B (as of 2 Nov 2026)
Biopharmaceutical company with a focus on neurological conditions.
Data as of 2 Nov 2026.
Recent capital raises
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 5 May 2025 | STATE STREET CORPORATION AND SUBSIDIARIES NAMED IN PARAGRAPH 7 TO THIS FORM | Entry | ?% → 5.01% | Filing ↗ |
| 3 Apr 2025 | The Vanguard Group, Inc. and its controlled entities | Entry | ?% → 5.023% | Filing ↗ |
| 12 Mar 2025 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities) | Entry | ?% → 5.023% | Filing ↗ |
| 6 Mar 2025 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities including Vanguard Investments Australia Ltd. and those listed in Annexure A) | Exit | ?% → 4.988% | Filing ↗ |
| 25 Feb 2025 | Vanguard Group (The Vanguard Group, Inc. and its controlled entities including Vanguard Investments Australia Ltd. and those listed in Annexure A) | Entry | ?% → 5.0% | Filing ↗ |
Director trades — on-market
| Date | Director | Trade | Source |
|---|---|---|---|
| 5 Mar 2026 | Joseph Basile | Bought 12,300 Ordinary shares | Filing ↗ |
| 8 Sept 2025 | Mr. Jonathan Pilcher | Sold 398,207 | Filing ↗ |
| 16 Apr 2025 | Joseph Basile | Bought 14,500 Ordinary shares | Filing ↗ |
| 16 Aug 2024 | Joseph Basile | Bought 6,406 Ordinary shares | Filing ↗ |
| 11 June 2024 | Joseph Basile | Bought 5,000 Ordinary shares | Filing ↗ |
Cash and runway
| Metric | Value | As of | Source |
|---|---|---|---|
| Cash | A$243M | 31 Mar 2024 | Filing ↗ |
Latest cash figure is from 31 Mar 2024 and may predate a later quarterly filing.
Ask about NEU in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has NEU raised money in the last year, and at what discount?
- What was NEU's latest cash position and runway?
Loading NEU…